168 related articles for article (PubMed ID: 33372039)
1. Subcellular Distribution of p53 by the p53-Responsive lncRNA
Mitra S; Muralidharan SV; Di Marco M; Juvvuna PK; Kosalai ST; Reischl S; Jachimowicz D; Subhash S; Raimondi I; Kurian L; Huarte M; Kogner P; Fischer M; Johnsen JI; Mondal T; Kanduri C
Cancer Res; 2021 Mar; 81(6):1457-1471. PubMed ID: 33372039
[TBL] [Abstract][Full Text] [Related]
2. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
3. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
4. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage.
Cai X; Liu X
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):16958-63. PubMed ID: 18952844
[TBL] [Abstract][Full Text] [Related]
7.
Al-Ghabkari A; Narendran A
Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
[No Abstract] [Full Text] [Related]
8. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
9. MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.
Rodriguez-Lopez AM; Xenaki D; Eden TO; Hickman JA; Chresta CM
Mol Pharmacol; 2001 Jan; 59(1):135-43. PubMed ID: 11125034
[TBL] [Abstract][Full Text] [Related]
10. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
11. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
[TBL] [Abstract][Full Text] [Related]
12. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
Gomes S; Raimundo L; Soares J; Loureiro JB; Leão M; Ramos H; Monteiro MN; Lemos A; Moreira J; Pinto M; Chlapek P; Veselska R; Sousa E; Saraiva L
Cancer Lett; 2019 Apr; 446():90-102. PubMed ID: 30664963
[TBL] [Abstract][Full Text] [Related]
13. The long non-coding RNA GAS5 differentially regulates cell cycle arrest and apoptosis through activation of BRCA1 and p53 in human neuroblastoma.
Mazar J; Rosado A; Shelley J; Marchica J; Westmoreland TJ
Oncotarget; 2017 Jan; 8(4):6589-6607. PubMed ID: 28035057
[TBL] [Abstract][Full Text] [Related]
14. Analysis of nuclear and cytoplasmic degradation of p53 in cells after stress.
Joseph TW; Moll UM
Methods Mol Biol; 2003; 234():211-7. PubMed ID: 12824534
[TBL] [Abstract][Full Text] [Related]
15. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
16. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.
Salas Fragomeni RA; Chung HW; Landesman Y; Senapedis W; Saint-Martin JR; Tsao H; Flaherty KT; Shacham S; Kauffman M; Cusack JC
Mol Cancer Ther; 2013 Jul; 12(7):1171-9. PubMed ID: 23615632
[TBL] [Abstract][Full Text] [Related]
17. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
18. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
[TBL] [Abstract][Full Text] [Related]
20. The p53 pathway and its inactivation in neuroblastoma.
Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
